AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 213 min read$ISRG

Intuitive Surgical (ISRG) Shares Dip Despite Strong Q3 Results o

Intuitive Surgical (ISRG) reported Q3 2026 revenues of $3.0B and EPS of $3.00, beating expectations but missing procedure growth targets. Shares declined due to lowered full-year outlook. ISRG is trading at $430.38, 32.3% below GF Value™ of $636.02, with a GF Score™ of 96/100. Insiders sold $93.4M in shares over 12 months.

Original reporting
gurufocus.com
Published Oct 21, 2026, 4:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 5:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ISRG
Bearish
high confidence
Mentioned
$ISRG
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ISRGBearishHigh
01

Why it matters

The earnings beat underscores robust core profitability, but the lowered guidance signals near‑term growth risk, likely prompting short‑term sell‑offs.

02

Market read

The earnings release provides fresh data that can shift trader positioning in ISRG and related med‑tech stocks.

03

What to watch

Strong recurring revenue from instruments and services could sustain long‑term growth despite short‑term procedural slowdown.

Relevance 8/10Novelty 8/10Timing: after earnings release

Background

Intuitive Surgical is a leading provider of robotic surgical systems, with a market cap over $150 B and a business model reliant on procedure volume.

Company-level read

Ticker impact

$ISRGBearishHigh confidence
Context

Intuitive Surgical reported Q3 2026 earnings beat but lowered full-year outlook, causing the stock to dip despite strong revenue and EPS.

Expected impact

likely pressure as the market prices in the weaker outlook

Evidence & confidence

The earnings beat is offset by a missed procedure growth target and a lowered full‑year growth forecast, which historically triggers sell‑offs in high‑growth med‑tech stocks.

Market effects

Sector

The med‑tech sector may see broader caution as growth expectations for robotic surgery are tempered.

Regional

U.S. healthcare stocks could experience modest pullback in the afternoon session.

Global

Limited to investors tracking U.S. medical‑device equities; no immediate global macro effect.

Counterpoint

What could challenge this read

The valuation gap (32% below intrinsic value) may present a buying opportunity if the outlook revision is temporary.

Key entities

  • Company
    Intuitive Surgical Inc.

    NASDAQ‑listed maker of da Vinci surgical robots.

Read at source← All news

StoryIntuitive Surgical posts Q3 beat but shares tumble on settlement charge and pricing cuts

Also covered by

3 outlets

Related articles

OCT 21
$ISRGHighAI 8/10

Intuitive Surgical Drops as $450 Million Charge Overshadows Beat

Intuitive Surgical (ISRG) reported Q3 revenue of $3.05B, up 22%, and adjusted earnings of $3.00 per share, beating expectations. However, shares fell due to a $450M antitrust settlement and a cautious growth outlook. GAAP earnings dropped to $1.49 per share, affected by the settlement. The company placed 546 da Vinci systems, with 315 being the newer da Vinci 5 platform.

finance.yahoo.com2 min
OCT 21
$ISRGHighAI 8/10

Intuitive’s shares fall 8% after tempering 2026 procedural growth outlook

Intuitive Surgical reported Q3 revenue of $3.01B, up 22% YoY, but shares fell 8% after lowering its 2026 robotic surgery procedure growth outlook to 14-15% from 13.5-15.5%. The company cited US and Chinese market headwinds. Q3 procedures grew 15% YoY, with 546 da Vinci robots placed. CEO Dave Rosa highlighted strong performance across platforms, including FDA clearance for da Vinci 5 in March 2024.

finance.yahoo.com2 min
OCT 21
$ISRGMed

Intuitive Surgical (ISRG) Q3 2026 Earnings Call Transcript

Intuitive Surgical (ISRG) reported strong Q3 2026 results, with da Vinci system placements up 28% globally. Da Vinci 5 and SP systems accounted for 65% of placements, and the company announced plans for a new manufacturing facility in Malaysia. ISRG also received several regulatory clearances and expects further reimbursement actions for Ion outside the U.S. The company settled a class action lawsuit related to third-party servicing of da Vinci systems.

finance.yahoo.com2 min
OCT 21
$ISRGMedAI 8/10

Stifel reiterates Intuitive Surgical stock rating after Q3 beat

Stifel maintained its Buy rating and $550 target on Intuitive Surgical (ISRG) after Q3 2026 results beat estimates. Revenue grew 20.66% YoY, with procedure growth of 10% in the U.S. and 20% internationally. Analysts have mixed views on the stock, with targets ranging from $400 to $500. Management expects strategic initiatives to boost growth.

investing.com2 min
OCT 21
$ISRGHighAI 8/10

Intuitive Surgical Stock Falls Despite da Vinci 5 Placements Jump

Intuitive Surgical (ISRG) reported Q3 non-GAAP EPS of $3.00, beating estimates, on revenue of $3.05B, also exceeding expectations. GAAP EPS fell due to a $450M litigation charge. Shares dropped 7.76% premarket. Revenue rose 22%, driven by procedure growth and higher lease revenue. Da Vinci system placements increased to 546 from 427 a year earlier, with 315 being the new da Vinci 5 model.

finance.yahoo.com2 min